18F-FMISO PET imaging and efficacy of eribulin in metastatic breast cancer

18F-FMISO PET imaging and efficacy of eribulin in metastatic breast cancer - 18F-FMISO PET imaging in metastatic breast cancer

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014173

Enrollment

Registered

2014-07-01

Start date

2014-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metastatic breast cancer

Interventions

18F-FMISO PET

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: patients over 20y.o. with evaluatable lesion of metastatic breast cancer who were planned eribulin treatment

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
SUV level of FMISO PET and the change after treatment of eribulin	—

Countries

Japan

Contacts

Public ContactMitsuchika Hosoda

Hokkaido University Hospital breast surgery

hosodam@seagreen.ocn.ne.jp011-706-7381

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026